At a glance
- Originator Bristol-Myers Squibb
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 27 Sep 1999 New profile
- 27 Sep 1999 Preclinical development for Thrombosis in USA (Unknown route)